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Primary adrenal insufficiency (PAI) is a potentially life-threatening condition that can present with
nonspecific features and can be difficult to diagnose. We undertook next generation sequencing in a
cohort of children and young adults with PAI of unknown etiology from around the world and
identified a heterozygous missense variant (rs6161, c.940G.A, p.Glu314Lys) in CYP11A1 in 19 in-
dividuals from 13 different families (allele frequency within undiagnosed PAI in our cohort, 0.102 vs
0.0026 in the Genome Aggregation Database; P , 0.0001). Seventeen individuals harbored a second
heterozygous rare disruptive variant in CYP11A1 and two had very rare synonymous changes in trans
(c.990G.A, Thr330 = ; c.1173C.T, Ser391 =). Although p.Glu314Lys is predicted to be benign and
showed no loss-of-function in anEscherichia coli assay system, in silico and in vitro studies revealed that
the rs6161/c.940G.A variant, plus the c.990G.A and c.1173C.T changes, affected splicing and that
p.Glu314Lys produces a nonfunctional protein in mammalian cells. Taken together, these find-
ings show that compound heterozygosity involving a relatively common and predicted “benign” variant
in CYP11A1 is a major contributor to PAI of unknown etiology, especially in European populations.
These observations have implications for personalizedmanagement and demonstrate how variants that
might be overlooked in standard analyses can be pathogenic when combined with other very rare
disruptive changes.
This article has been published under the terms of the Creative Commons Attribution License (CC
BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricteduse, distribution, and
reproduction in any medium, provided the original author and source are credited. Copyright for
this article is retained by the author(s).
Freeform/KeyWords:Addison disease, silent variant, side chain cleavage enzyme, cytochrome
p450scc, CYP11A1
The first step in steroidogenesis involves cleavage of cholesterol to pregnenolone by the
cytochrome P450 side chain cleavage enzyme (CYP11A1). CYP11A1 is encoded by CYP11A1
and is expressed in key steroidogenic tissues such as the adrenal gland and gonads. Further
tissue-specific enzymatic steps lead to production of all other steroid hormones. In the ad-
renal gland, this ultimately results in the production of glucocorticoids (cortisol) and min-
eralocorticoids (aldosterone) and weak androgens, and in the gonads, the production of sex
steroids (estrogen and testosterone) [1].
Complete loss of CYP11A1 prevents biosynthesis of all steroid hormones andwas predicted
to be incompatible with life owing to the inability of the placenta to maintain a pregnancy
without progesterone production from fetally derived tissue [2]. However, it has become clear
that biallelic mutations in CYP11A1 are compatible with survival to term. Defects in
CYP11A1 can cause a range of phenotypes: from classic CYP11A1 deficiency with severe
disruption of adrenal and gonadal steroidogenesis, causing salt-losing adrenal insufficiency
and gonadal hormone deficiency, to very mild phenotypes in which only glucocorticoids are
affected [OMIM (Online Mendelian Inheritance in Man) no. 613743] [3–14] (Supplemental
Table 1).
Massively parallel sequencing technologies have expedited discovery of disease-causing
variants. However, assigning causality to the identified variants can be complex. When
filtering for causal variants, synonymous changes (which do not affect amino acid coding)
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could be discarded, without considering their allele frequency. In addition, variants predicted
to be “benign” at the protein level could also be deselected. Furthermore, splice site changes
can only be considered if they alter the canonical GT…AG motifs bordering introns. Such
stringency could result in missing pathogenic and clinically relevant variants.
In the present study, we have investigated a large cohort of children and young adults with
primary adrenal insufficiency (PAI) of unknown etiology. We found that compound het-
erozygous variants in CYP11A1 involving rs6161 (c.940G.A; p.Glu314Lys) were surpris-
ingly common and that altered splicing should be considered when predicted benign or very
rare synonymous changes are found.
1. Material and Methods
A. Subjects and Sequencing
The main focus of the present study was to assess CYP11A1 in subjects with PAI of unknown
etiology. The inclusion criteria included evidence of low cortisol, an attenuated cortisol re-
sponse on cosyntropin stimulation testing, and elevated ACTH, with clinical signs of cortisol
insufficiency and hyperpigmentation [15, 16] (Table 1). Some subjects also had elevated
plasma renin activity and low aldosterone and/or electrolyte disturbances (hyponatremia,
hyperkalemia) consistent with mineralocorticoid insufficiency.
The exclusion criteria were an established biochemical and/or genetic diagnosis, such as
other forms of congenital adrenal hyperplasia (e.g., 21-hydroxylase deficiency, 11b-
hydroxylase deficiency, 3b-hydroxysteroid-dehydrogenase deficiency type 2), autoimmune
adrenalitis, metabolic disorders or physical cause of adrenal insufficiency (e.g. hemor-
rhage, infection), or known genetic causes of familial glucocorticoid deficiency or adrenal
hypoplasia. Individuals with isolated hypospadias, 46,XY disorders of sex development, or
intrauterine growth restriction (,2 SD) with associated adrenal insufficiency were
also excluded.
The patients were recruited from three main cohorts: (i) The “Barts/Royal London
Hospital/Queen Mary University of London,” which included 43 individuals with PAI of
unknown etiology, who were assessed by exome sequencing, targeted panel testing, or direct
Sanger sequencing; (ii) the “UCL/Great Ormond Street Institute of Child Health” cohort,
which included 25 individuals with PAI of unknown etiology, who were assessed by targeted
panel testing; and (iii) the “Turkish” cohort, which included 9 individuals with PAI of un-
known etiology, who were assessed by targeted panel and exome sequencing. Using this
approach, the prevalence of CYP11A1 c.940G.A as a cause of PAI in a cohort (n = 77) with no
current diagnosis could be determined (Supplemental Table 2).
To establish the prevalence of CYP11A1 c.940G.A as a cause of PAI in these cohorts in
general, the total numbers of individuals recruited over the years were calculated (n = 395).
Although considerable overlap was present in the clinical features, the “Barts/Royal London
Hospital/Queen Mary University of London” cohort (total n = 256) focused more on classic
“familial glucocorticoid deficiency” [e.g., MC2R, MRAP, NNT, AAAS, STAR (steroidogenic
acute regulatory protein),MCM4]. The “UCL/Great Ormond Street Institute of Child Health”
cohort (total n = 57) focused more on adrenal hypoplasia (e.g., NR0B1, with potential non-
classic STAR,NNT, and severeMC2R among the diagnoses; almost 80% of the children were
receivingmineralocorticoid replacement). The “Turkish” cohort (total n = 82) included a range
of diagnoses recently reported (e.g., MC2R, CYP11A1, MRAP, NNT) and represented in-
dividuals and families with high consanguinity [3]. For the present analysis, individuals with
hypospadias or 46,XY disorders of sexual development were excluded, and children with the
classic forms of congenital adrenal hyperplasia (e.g., 21-hydroxylase), autoimmune disorders,
or physical causes would not have been referred. Finally, one family (three individuals) from
Australia was included because the diagnosis had been reached by exome sequencing.
However, that kindred was not included in prevalence data because they did not form a part
of a cohort.
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A-1. DNA samples
Studies were performed with the approval of the local ethics committees (Outer North East
London research ethics committee, reference number, 09/H0701/12; London-Chelsea National
Research Ethics Service committee, reference number, 13/LO/0224; London-Bloomsbury Na-
tional Research Ethics Service committee, reference number, 07/Q0508/24; the Mater Hospital
ethics committee, reference number, 1931C). After ethical approval and informed consent from
the individuals or their families, genomic DNA was extracted from whole blood of the affected
individuals, and their parents and unaffected siblings, if available.
A-2. Sequencing
Whole exome sequencing was used for subjects 1, 11A, 11B, and 11C; CYP11A1 alone was
sequenced for subjects 12 and 13. All other subjects were analyzed using the HaloPlex
targeted capture array (Agilent Technologies, Inc., Santa Clara, CA) [3, 15] (see section A-4).
Sanger sequencing was used to confirm segregation of the variants in the kindreds in which
the parents and/or unaffected siblings were available.
A-3. Exome sequencing
Subject 1 was sequenced as described previously [15]. For individuals 11A, 11B, and 11C,
exome sequencing libraries were constructed using the Nextera Rapid Capture Exome
(Illumina, Inc., San Diego, CA), according to the manufacturer’s recommendations. In brief,
50 ng of genomic DNA was tagmented (fragmented and adapter sequences added) using the
Nextera transposomes. Tagmented samples were purified, and the fragment size was con-
firmed using the 2100 Bioanalyser (Agilent Technologies, Inc.). The libraries were denatured
into single-strand DNA, and biotin-labeled probes specific to the target regions were used for
Rapid Capture hybridization. The pool was enriched for the desired regions by adding
streptavidin beads that bind to the biotinylated probes. Biotinylated DNA fragments bound
to the streptavidin beads were magnetically pulled down from the solution. The enriched
DNA fragments were then eluted from the beads and hybridized for a second Rapid Capture
hybridization. A second magnetic bead cleanup was performed. The final libraries were
analyzed using the 2100 Bioanalyzer and DNA 1000 chip kit (Agilent Technologies, Inc.) to
determine the quantity and size of the enriched fragments.
Massive parallel sequencing was performed with six samples per flow cell lane via the
Illumina HiSeq2000 platform and version 3 SBS reagents to generate 100 bp paired-end
reads. After demultiplexing, the Illumina Data Analysis Pipeline software (CASAVA, version
1.8.2) was used for initial base calling. Sequence data were aligned to the current build of the
human genome (UCSC Genome Browser, hg19, released February 2009) via the Novoalign
alignment tool (version 2.08.02 1). Sequence alignment files were converted using the
SAMtools, version 0.1.14, and Picard tools, version 1.42. Single nucleotide polymorphisms
(SNPs) and indels were called with the Genome Analysis Toolkit, version 5506, and anno-
tated using ANNOVAR.
Further analysis of sequence data was performed with custom scripts using R and Bio-
conductor. We retained good-quality SNPs and indels (minimum depth of coverage for SNP
calling .10-fold for homozygous SNPs; .15-fold for heterozygous SNPs). Additionally, we used
variants that had passed the Genome Analysis Toolkit Variant quality score recalibration.
The remaining SNPs and indels were assessed according to the prediction of potentially
damaging consequence [“nonsynonymous single nucleotide variant” (SNV) “splicing,” “frameshift
substitution,” “stopgain SNV,” “stoploss SNV”] using both RefSeq and UCSC transcripts.
Further filtering excluded SNPs with a minor allele frequency (MAF) .0.01 observed in the
National Center for Biotechnology Information dbSNP, release 137 (available at: www.ncbi.nlm.
nih.gov/SNP/), 1000 Genomes, 1000 Genomes small indels (called the DINDEL program), the
SNPs of 46Genomes release byComplete Genomics, and otherwhole exomes from.3000 control
doi: 10.1210/js.2018-00130 | Journal of the Endocrine Society | 207
samples run internally using similar capture technology. Variants not present in any of these
databases were considered novel.
A-4. HaloPlex targeted gene panel and next generation sequencing
A custom HaloPlex DNA target enrichment panel (Agilent Technologies, Inc., Santa Clara,
CA) was designed (SureDesign) to capture 160 known and candidate genes involved in
adrenal development and function. All coding exons and 100 base pairs of the intronic
flanking sequence were included. The panel covered known genes potentially causing PAI,
congenital adrenal hyperplasia-related genes, potential syndrome-related genes, and can-
didate genes based on data from biochemical and/or biological pathways, mouse models of
adrenal dysfunction, and gene expression [3].
Sequence capture was performed according to the HaloPlex Target Enrichment Protocol,
version D.5 (Agilent Technologies, Inc., Santa Clara, CA) for Illumina sequencing. Patient ge-
nomicDNAaliquots (225 ng)were processed in batches of 24 sampleswith an enrichment control
DNA sample as a positive control. Sequencing was performed using a MiSeq next generation
sequencer (Illumina, Inc., San Diego, CA). Sequence alignment and variant calling were per-
formed using SureCall, version 2.0, software (Agilent Technologies, Inc., Santa Clara, CA).
A-5. Sanger sequencing
Potential disease causing variants were confirmed using PCR and Sanger sequencing.
CYP11A1 exons of interest, including intronic boundaries, were amplified by PCR using
specific primers (Supplemental Table 3). The reaction mixture contained 100 ng DNA
template, 13PCR buffer, 200mM for each deoxyribonucleotide triphosphate (dNTP), 200 nM
for each primer, and 1 U Taq DNA polymerase (Sigma-Aldrich, St. Louis, MO). The cycling
conditions were 95°C for 5 minutes (1 cycle); 95°C for 30 seconds, 55°C for 30 seconds, and
72°C for 30 seconds (30 cycles); and 72°C for 5 minutes. The PCR products were visualized on
1% agarose gel and sequenced using the ABI Prism Big Dye sequencing kit and an ABI 3700
automated DNA sequencer (Applied Biosystems, Foster City, CA), in accordance with the
manufacturer’s instructions.
A-6. Sequence interpretation
Variants were considered highly likely to be pathogenic if they segregatedwith the phenotype
with an appropriate inheritance pattern within families, were determined damaging or likely
damaging by several bioinformatic prediction models (Ensembl Variant Effector Predictor;
SIFT; PolyPhen-2; and Mutation Taster; see the Appendix) and/or if they had been reported
in association with adrenal insufficiency previously. In addition, other missense and syn-
onymous changes with a MAF ,3% in the Exome Aggregation Consortium (ExAC) browser
(Exome Aggregation Consortium, Cambridge, MA) were considered.
A-7. In Silico Analysis of Variants
MAFs were determined from the ExAC and Genome Aggregation Database (gnomAD)
browsers. The functionality of the variants was assessed at all levels using the variant effect
predictor and MutationTaster. Splice function was assessed using Human Splicing Finder,
version 3.0, SpliceAid, and ESEfinder (see the Appendix).
B. Statistical Analysis
The difference in allele frequencies between subjects (counting one proband per family to
avoid cascade testing bias) and controls (MAF from gnoMAD non-Finnish Europeans, de-
termined from ExAC data) was measured using x2 test with Yates’ correction.
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C. In Vitro Splicing Assay
An in vitro splicing assay was designed using the commercially obtained Exontrap cloning
vector pET01 (MoBiTec GmbH, Go¨ttingen, Germany) containing an intronic sequence
interrupted by a multiple cloning site. DNA fragments of interest were amplified using a
standard PCR protocol and specifically designed primers (Supplemental Table 4) containing a
restriction enzyme target site forXbaI. The cycling conditionswere as follows: 95°C for 5minutes,
153 [95°C for 30 seconds, 70°C for 30 seconds (21°C per cycle), 72°C for 30 seconds], 303 (95°C
for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds), and 72°C for 5 minutes. PCR products
were sequenced as above (section A-5), column purified using the QIAquick® PCR Purification
Kit according to the manufacturer’s protocol, and cloned into the Exontrap cloning vector pET01
(MoBiTec GmbH). The cloned sequences were verified by Sanger sequencing to ensure the
fragment was in the correct orientation using pET01 specific primers [ET PRIM 06 (forward)
GCGAAGTGGAGGATCCACAAG and ET PRIM 07 (reverse) ACCCGGATCCAGTTGTGCCA].
Wild-type (pET01-WT) or pET01 mutant plasmids were transfected into HEK293 cells using
Lipofectamine® reagent (Thermo Fisher Scientific, Waltham, MA). Total RNA, obtained from
cells 24 hours after transfection, was subjected to RT-PCR to generate cDNA with primer
GATCCACGATGC (MoBiTec GmbH) and amplifying with primers within the 5ʹ and 3ʹ exons in
the pET01 vector primer 02 (GAGGGATCCGCTTCCTGGCCC) and primer 03 (reverse sequence
CTCCCGGGCCACCTCCAGTGCC; Supplemental Table 5). Amplification productswere assessed
on a 2% agarose gel.
D. Fibroblast Isolation, Culture, and Expansion
Fibroblast isolation and culture was performed as described previously [17]. In brief, a 4-mm
punch biopsy from the upper arm (patient 1 and his parents) was immediately incubated with
isolation medium [DMEM supplemented with 10% (v/v) fetal bovine serum (FBS), and 1%
penicillin/streptomycin (P/S)] in a 15-mL falcon tube. Next, 1-mm2 cubes of skin sample were
digested using DMEM/high glucose, 20% FBS (v/v), 0.25% collagenase type I, 0.05%DNAse-I,
and 1% P/S (Sigma-Aldrich) at 37°C overnight in a 15-ml falcon tube. After centrifugation for
5minutes at 1000 rpm, the pellet was resuspended in 5mL of isolationmedium before plating
in gelatin coated T25 flasks. The cells were kept in human fibroblast media [DMEM/high
glucose with sodium pyruvate and L-glutamine, 20% FBS (v/v) and 1% P/S].
E. RNA Extraction and PCR Analysis
Total RNA was purified using an RNeasy Mini Kit (model no. 74106; Qiagen, Valencia, CA).
RNase-Free DNase Set (model no. 79254; Qiagen) was used to eliminate genomic DNA con-
tamination. Next, 50 ng of RNA was incubated with 60 ng/mL of random primers for 5 minutes
at 70°C, followed by incubationwith 500mMdNTPs, 40U of RNAse inhibitor, 200U ofMoloney
murine leukemia virus RT and 13 Moloney murine leukemia virus buffer for 10 minutes at
25°C, 90 minutes at 42°C, and 15minutes at 70°C to generate cDNA. PCR amplifications were
performed using 2 ng of cDNA, dNTPs of 200 mM, and Q5 DNA polymerase (model no. M0491;
NewEnglandBiolabs, Inc.) using primers in exons 3 and 6 ofCYP11A1 (Supplemental Table 6).
F. Protein Expression in Escherichia coli and Purification
The F2 construct of human CYP11A1, adrenodoxin (Adx; ferredoxin), and ferredoxin re-
ductase was provided by Professor Walter L. Miller (University of California, San Fran-
cisco, CA) [18]. From the construct, three different cDNAs were constructed separately
using PCR. A cDNA encoding human CYP11A1 in pcDNA3 was amplified by PCR to remove
the 39-amino acidN-terminal mitochondria-targeting sequence and to add aHis6-tag at the
C-terminus. The primers were 11A1-sense 50-ATACATATGGCGTCTACCCGTTCTCCT-
CGCCCCTTCAATGAGAT-30; 11A1-antisense 50-AGAATTCTCAGTGATGGTGATGGTG-
ATGCTGCTGGGTTGCTTCCT-30. The PCR products were then cloned into the pET-17b
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vector viaNdeI/EcoRI restriction sites. The cDNA for ferredoxin reductase was amplified by
PCR to include the His6-tag at the C-terminus and cloned into pET-17b via NdeI/EcoRI
restriction sites. The primers were FdR-sense 50-ATACATATGGCGTCTACCCAGGAAA-
AGACCCCACAG-30; and FdR-antisense 50-AGAATTCTCAATGGTGATGGTGATGGT-
GGTGGCCCAGGAGGC-GCA-30. The sequence coding for mature human Adx (amino acids
62 to 184) was amplified by PCR to include the His6-tag at the N-terminus and cloned into
pLW01 via NcoI/EcoRI restriction sites. The primers were Adx-sense 50-TATACCATGG-
CACACCATCACCATCACCATTCATCAG-AAGATAAAATAACAGTC-30, and Adx-antisense
50-ATGAATTCTCAGGAGGTCTTGCCC-AC-30. The QuikChange Lightning kit site-directed
mutagenesis (Agilent Technologies, Inc.) was used to generate the p.Glu314Lys variants for
CYP11A1 in both pcDNA3 and pET-17b. The primers were sense 50-GCAAGATGTCCTTC-
AAGGACATCAAGGCC-30; and antisense 50-GGCCTTGATGTCCTTGAAGGACATCTTGC-30.
Sanger sequencing of plasmid constructs confirmed the intended site-specific mutations and
ensured the lack of other substitutions. WT and Glu314Lys plasmid DNAs were isolated using a
Qiagen Maxi Prep kit.
Human Adx was expressed in E. coli strain C41(DE3) and purified as described previously
[19]. Human ferredoxin reductase [20], CYP11A1 WT [19], and Glu314Lys were expressed in
C41(DE3) with pGro7 (Thermo Fisher Scientific) and purified as described previously [21]. In
brief, Fernbach flasks containing 1 L of Terrific Broth (supplemented with 0.5 mM
5-aminolevulinic acid for CYP11A1; Sigma-Aldrich) with 100 mg/mL ampicillin (and 20 mg/mL
chloramphenicol for pGro7; Sigma-Aldrich) were inoculated with 20 mL of an overnight pre-
culture. The cells were grown at 37°C with shaking at 250 rpm until the A600 reached 1.0 to 1.4
AU, at which time the culture was induced with 0.4 mM isopropyl b-D-1-thiogalactopyranoside
(supplemented with 4 g/L arabinose for ferredoxin reductase and P450s) and grown for 20 to
48 hours at 28°C. After cell lysis with French press in buffer A (sterile phosphate-buffered saline
containing 20% glycerol for ferredoxin reductase andCYP11A1), the recombinant P450 proteins
were solubilized using 1% cholate (Chem-Impex International) and 0.5% NP-40. After cen-
trifugation at 70,000g for 18 minutes, the supernatant was mixed with 3 to 5 mL Ni-NTA
affinity resin, and polyhistidine-tagged proteins were eluted with 10 mL of 250 mM imidazole,
followed by buffer exchange using PD-10 columns. Purified CYP11A1 preparations showed a
specific content of 8 to 12 nmol P450/mg protein with 3% to 10% P420.
G. Reconstituted Enzyme Assays
In a 2-mL polypropylene tube, purified human CYP11A1 (10 pmol, WT or Glu314Lys) was
mixed with an equal amount of ferredoxin reductase, 40-fold molar excess of Adx, and
dilauroyl phosphatidyl choline in ,10 mL volume and incubated for 5 minutes. The reaction
mixture was then diluted to 0.2 mL with 50 mM HEPES buffer (pH 7.4), 4 mM MgCl2, 0.2%
Tween 20, and substrates 22R-hydroxycholesterol (in ethanol) or cholesterol (in methyl-
b-cyclodextrin inclusion complexes). The resulting mixture was preincubated at 37°C for
3 minutes before adding NADPH (1 mM) and incubating at 37°C for another 20 minutes. The
reaction mixture was extracted with 1 mL dichloromethane, and the organic phase was dried
under nitrogen flow. The steroids were reconstituted in 70 mL of methanol, and a solution of
0.1 mL 100 mM potassium phosphate buffer (pH 7.4) containing 10 mL of cholesterol oxidase
(100 U/mL) was added with 3 mL internal standard (1 mM dehydroepiandrosterone). The
mixture was incubated at 30°C for 6 hours to convert the product pregnenolone to pro-
gesterone and the internal standard to androstenedione. The mixture was extracted with
1 mL of dichloromethane, and the organic layer was dried under nitrogen flow.
G-1. Chromatography, data acquisition, and determination of kinetic constants
Reaction products were analyzed using an Agilent 1260 Infinity HPLC system with an ul-
traviolet detector. Extracted steroid products were dissolved in 20 mL of methanol, and 5 mL
injections were resolved with a 50 3 2.1-mm, 2.6-mm, C8 Kinetex column (Phenomenex,
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Torrance, CA), equipped with a guard column at a flow rate of 0.4 mL/min. A methanol/water
linear gradient was used: 27% methanol from 0 to 0.5 minute, 39% to 16 minutes, 44% to
20 minutes, 60% to 22 minutes, 71% to 30 minutes, 75% to 30.5 minutes, and 27% to 33
minutes. The steroids progesterone and androstenedione were identified by the retention
times of external standards chromatographed at the beginning and end of the experiments,
and the data were processed using Laura4 software (LabLogic) and graphed with GraphPad
Prism, version 6 (GraphPad Software, San Diego, CA).
G-2. Immunoblotting
One day before transfection, HEK-293T cells were plated in six-well plates at 50% confluency.
The next day, the cells were transiently transfected with 1 mg plasmid DNA/well and 3 mL
FuGENE 6 transfection reagent/well (Promega, Madison, WI). The transfected cells were
treated with 25mMcycloheximide for the specified period, as indicated, andwhole cell protein
extracts were collected 48 hours after transfection using radioimmunoprecipitation assay
buffer (Sigma-Aldrich) supplemented with Mini Protease Inhibitor Tablets (Roche). Lysates
were briefly sonicated for ~10 seconds, centrifuged to remove cellular debris, and resolved
(25 mg total protein) on a 4% to 20% SDS-PAGE gel (Novex). The proteins were transferred to a
polyvinylidene difluoridemembrane (Millipore, Billerica,MA), blockedwith 5% fat-freemilk in
Tris-buffered saline with 0.1% Tween-20, and detected by rabbit anti-CYP11A1 at 1:5000
dilution [22] (RRID: AB_2747382 [23]; a generous gift from Walter Miller); mouse anti–
glyceraldehyde 3-phosphate dehydrogenase at 1:10,000 dilution (RRID: AB_2107426 [24])
served as a loading control. Immunoreactive bands were visualized on film using horseradish
peroxidase-conjugated mouse or rabbit secondary antibodies (1:5000; RRID: AB_330924 [25]
and RRID: AB_2099233 [26], respectively) combined with SuperSignal West Chemiluminescence
Substrate (Pierce, Thermo Fisher).
G-3. Activity assay in intact cells
V79 hamster lung cells were plated in 12-well plates at ~70% confluency. The next day, the
cells were transiently transfected with 1 mg/well pcDNA3-CYP11A1 plasmids (WT or mu-
tations) in triplicate using TransIT-LT1 transfection reagent (Mirus) according the manu-
facturer’s instructions. At 24 hours after transfection, the cells were incubated with 1 mL of
serum-free medium containing 22R-hydroxycholesterol (5 mM) and dehydroepiandrosterone
(control steroid, 1mM). Aliquots of themediumwere removed at 6 and 24 hours, and 0.1mL of
each sample was mixed with deuterium-labeled internal standards and extracted with 1 mL
methyl tert-butyl ether. Pregnenolone product was converted to the oxime with hydroxyl-
amine in aqueous ammonia and quantified using tandem mass spectrometry, as described
previously [27].
2. Results
A. Prevalence of the CYP11A1 c.940G.A Variant in PAI
Initially, we undertook whole exome or targeted panel sequencing in 77 individuals or family
members with PAI of unknown etiology from the three main cohorts studied (Supplemental
Table 2). Sixteen individuals from 12 different families were found to harbor the rs6161
variant in CYP11A1 (chr15:74635368C.T; c.940G.A), together with another very rare
heterozygous variant (Table 2; families 1 to 10, 12, and 13), for an overall prevalence of
CYP11A1 c.940G.A associated with PAI of unknown etiology of 20.8% (16 of 77) and a
prevalence of 4.1% (16 of 395) in our cohorts of patients with adrenal insufficiency overall
(Supplemental Table 2). Evenwhen only one probandwas counted per family to avoid cascade
testing bias, theMAF of rs6161 was enriched in our cohort, with a frequency of 0.102 (12 of 59
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compared with a MAF of 0.0026 across all gnomAD populations or 0.0042 in non-Finnish
Europeans; x2 P , 0.0001). Thus, ~1 in 200 of the population (and 1 in 120 Europeans) are
heterozygous carriers of this variant compared with 1 in 5 of the undiagnosed PAI study
group. Finally, a further family from Australia with three affected individuals was identified
to have this variant, together with a second change, and was included in our series (Table 1;
family 11). Consequently, compound heterozygosity of rs6161 with another disruptive
variant in CYP11A1 was identified in 19 individuals from 13 families in total. Validation of
the variants and segregation with disease was confirmed by Sanger sequencing in these
patients and in their family members, if possible, showing that the variants occurred in trans
(Table 2; Fig. 1).
The clinical details for the affected individuals are presented in Table 1. Diagnosis oc-
curred at variable ages from 6 months to 16 years. In six children or young people (6 of 19;
32%), the diagnosis was facilitated by a history of PAI in their siblings. Hyperpigmentation
was often present at the time of diagnosis (13 of 19; 68%), and many children had a history of
ketotic hypoglycemia or hypoglycemic convulsions (10 of 19; 53%). All the children had been
treated with glucocorticoid replacement, and almost one-half of them had received miner-
alocorticoid replacement (8 of 19; 42%). Most children had developed normally in puberty,
although four boys experienced pubertal delay (four of nine postpubertal males; 44%), and
mildly elevated gonadotropin concentrations were found in several adults.
The protein change resulting from the recurrent rs6161, p.Glu314Lys, was predicted to be
benign by commonly used algorithms such as SIFT (Sorting Intolerant from Tolerant) and
PolyPhen-2 but “disease causing” by MutationTaster2. Furthermore, the nucleotide change,
in exon 5, is predicted to affect splicing (Human Splicing Finder 3.0; ESEfinder; Supple-
mental Table 7). The trans variants were all extremely rare, with MAF ranging from 0 to
2.2 3 1025 in gnomAD (Table 2). In many cases, the variant resulted in an obviously del-
eterious effect; an early stop gain mutation (p.Arg120Ter, p.Arg439Ter, and p.Arg424Ter), a
deletion or insertion causing frameshift and premature stop codon (c.566dupC, c.835delA,
and c.790_802del), or a canonical splice site change likely to cause skipping of the adjacent
exon and giving rise to a prematurely truncated mRNA (c.1158-2A.G and c.426-2A.G).
These alleles are liable to be destroyed by nonsense-mediated mRNA decay (NMD). The
missense variants p.Leu335Pro, seen in two siblings (family 5) and the p.Arg460Trp, seen in
family 13, are in conserved residues and, on analysis, were predicted deleterious (SIFT) or
Figure 1. Position of variants in CYP11A1 genomic/pre-mRNA sequence found in this series
of patients with PAI. Boxed in bold, the three predicted benign or synonymous variants
assessed for their effect on splicing; SNP rs6161 (c.940G.A, p.Glu314Lys) is 110 bp from the
start and 51 bp from the end of exon 5, c.990G.A (p.Thr330 =) occurs at the last base of
exon 5, and c.1173C.T (p.Ser391 =) is 16 bp from the start of exon 7.
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probably damaging (PolyPhen). However, most intriguingly, two very rare synonymous
variants were observed (c.990G.A and c.1173C.T), with no predicted amino acid change
(Thr330 = and Ser391 =) in exons 5 and 7, respectively (Fig. 1). Bothwere designated “disease-
causing” by MutationTaster2 and predicted to alter splicing (Human Splicing Finder, 3.0,
results in Supplemental Tables 8 and 9).
B. Investigation of Splicing
To investigate the potential splicing effects of these variants, a series of functional studies
were undertaken. SNP rs6161 (c.940G.A) is within exon 5, 51 bp upstream of the natural
splice donor site of intron 6; c.990G.A occurs at the last base of exon 5; and c.1173C.T is
within exon 7, 16 bp downstream of natural acceptor site of intron 6 (Fig. 1). Using minigene
constructs (Fig. 2A), the WT allele (c.940G) showed inclusion of exon 5, but the variant allele
(c.940A) caused exon skipping (Fig. 2B). Similarly, we showed that variant c.990A caused
exon 5 skipping, and variant c.1173T caused complete skipping of exon 7 (Fig. 2B). The WT
exon 7, c.1173C, has also been reported to show a degree of exon skipping in vitro, consistent
with the skipping of this exon in certain transcripts (CD013982) reported by Jin et al. [28]. In
each instance, exon skipping would result in a frameshift and premature translation-
termination codon, p.Ala277AspfsTer11 (for exon 5 variants) and p.Leu387HisfsTer29 (for
exon 7 variant), if themessagewas not destroyed in vivo byNMD. Sanger sequencing of cDNA
fragments confirmed the variant caused the skipping of its containing exon in each case, with
no evidence of cryptic splice site usage (data not shown).
To investigate the potential splice effects in vivo, we studied genomicDNA andRNA-derived
cDNA in fibroblasts from subject 1 and his parents. By PCR of exon 5 in genomic DNA, it was
confirmed that he had inherited the c.940G.A variant from his mother and the c.990G.A
variant from his father (Fig. 3A). PCR of genomic DNA demonstrated that both alleles were
equally represented (data not shown). However, at the RNA level, the absence of the c.990A
allele was complete, with no exon skipped RNA detected by RT-PCR from exon 4 to 6 (Fig. 3A).
Also, both the patient’s and the father’s sequences showed WT c.990G only (Fig. 3B). This
findingwould be consistent withNMDof the variantRNA species. In contrast, the c.940A allele
showed evidence of skipping of exon 5, alongside production of a normally spliced, exon 5-
containing, transcript. In the subject’s and his mother’s RNA, two bands were seen, the upper
corresponding to exons 4-5-6 and the lower consisting of a transcript lacking exon 5 (bands at
384 and 223 bp, respectively, in Fig. 3A; confirmed by Sanger sequencing, data not shown). As
expected, the patient’s RNA contained only the mutant c.940A transcript at this position,
because the paternal “WT” allele had presumably been degraded by NMD. In the mother, both
c.940A and c.940G transcripts were detected, with the c.940A less abundant than the WT,
consistent with exon skipping and NMD for most of the variant allele (see the relative height of
the peaks for the mutant “A” and WT “G” seen in the mother’s RNA; Fig. 3B, arrow).
C. Assessment of Protein Function
Given the likelihood, therefore, that some of the c.940A (rs6161) transcripts will be translated
into protein, we evaluated the function of the resultant mutant p.Glu314Lys protein. The
mutation was re-created by site-directed mutagenesis, expressed in E. coli, and the catalytic
activity of CYP11A1 was measured by assays of cholesterol and 22R-hydroxycholesterol
conversion to pregnenolone. Despite the substitution of negatively charged Glu314 with a
positively charged lysine residue, the mutant enzyme exhibited similar side-chain cleavage
activities to WT CYP11A1 with either substrate (Fig. 4A and 4B). However, when cDNA
encoding p.314Lys was transfected into HEK-293 cells, the protein was truncated (degraded),
and the half-life after cycloheximide treatment was much shorter than that for WT (Fig. 4C).
The truncated protein was consistent in size with potential proteolytic cleavage of the protein
around the p.Glu314Lys change and, together with the splicing results, suggests relatively
little functional CYP11A1 would be produced from this allele. To ascertain whether enough
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protein would escape degradation in intact cells to produce pregnenolone and to test for activity
in the other two identified missense mutations, V79 cells were transfected with pcDNA3
expression plasmid encoding WT CYP11A1 or the three mutations. Pregnenolone formation
from 22R-hydroxycholesterol was measured using tandem mass spectrometry. Mutation p.
Arg460Trp demonstrated ,1% of WT activity. In contrast, mutations p.Glu314Lys and p.
Leu335Pro yielded no time-dependent pregnenolone formation (Table 3).
3. Discussion
PAI is a life-threatening condition. Glucocorticoid replacement is central to the management
of PAI, with some patients also requiring mineralocorticoid replacement. Approximately 20
different genetic causes of PAI have been identified to date (www.icped.org). However, in a
substantial proportion of individuals, the cause is not currently known.
The enzyme CYP11A1 plays a key role in the initial steps of steroidogenesis by catalyzing
the cleavage of cholesterol to pregnenolone. Children with marked disruption of this enzyme
Figure 2. An in vitro assay revealed aberrant splicing of variants c.940G.A, c.990G.A, and
c.1173C.T. (A) Minigene construction. Diagram of exon 5 and parts of flanking introns 4 and
5, inserted into the MCS of the pET01 construct (Lower). In the pET01 construct, the intron
containing the MCS is flanked by the 5ʹ-donor and 3ʹ-acceptor splice sites of preproinsulin
5ʹ and 3ʹ exons, respectively (green arrows) (http://www.mobitec.com/cms/products/bio/
04_vector_sys/exontrap.html). The expression of this vector sequence was driven by the
promoter present in the long terminal repeat of Rous sarcoma virus, followed by a short
stretch of a eukaryotic gene (phosphatase). The sequences containing the mutations detected
in CYP11A1 exons 5 and 7 (mutant) or those that did not (WT) were cloned into the MCS of
pET01. The primers used in the RT-PCR experiments within the preproinsulin 5ʹ and 3ʹ
exons are indicated by the black arrows (Supplemental Table 5). (B) Representative results
of RT-PCR analysis using HEK293 cells transfected with an empty pET01 vector (empty
vector), the pET01 vector containing the WT exon or the mutant exon: (Left) the c.940A in
exon 5, (Middle) the c.990A change in exon 5, (Right) the C.1174T change in exon 7. A
transcript of 225 bp was observed in the empty and mutant vector RT-PCRs, for all variants
investigated, corresponding to the two-exon amplification product resulting from splicing of
the preproinsulin 50 and 30 exons from the vector. For WT vectors containing c.940G and
c.990G, a 386 bp transcript was observed corresponding to the three-exon amplification
product resulting from correct splicing of CYP11A1 exon 5 between the two vector exons. The
intermediate band for exon 5 constructs, at ~350 bp (asterisk), was shown to be a mixture of
a sequence that included both 386- and 225-bp bands. For WT c.1173C, a 304-bp transcript
corresponding to the size of the three-exon amplification product resulting from correct splicing
of CYP11A1 exon 7 was observed. Sanger sequencing confirmed these findings (data not shown).
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typically present with severe salt-losing adrenal insufficiency in the first few days of life and a
complete block in gonadal steroidogenesis, with female-typical external genitalia in 46,XY
infants or a lack of puberty in 46,XX girls [3–5, 9–14].More recently, partial loss-of-function of
CYP11A1 has been reported in children with delayed-onset adrenal insufficiency and hy-
pospadias or glucocorticoid insufficiency alone [6–8]. The glucocorticoid pathway seems
especially vulnerable to loss of CYP11A1 activity, potentially owing to the much greater
molar concentrations of cortisol required, and even low levels of residual enzyme activity
appear to be sufficient for fetal gonadal steroidogenesis (Supplemental Table 1) [6–8]. Similar
findings have been shown for STAR, a related protein involved in facilitating cholesterol
transfer into mitochondria, where complete disruption causes congenital lipoid adrenal
hyperplasia affecting the adrenal and sex hormones, but partial dysfunction is associated
with predominant glucocorticoid insufficiency [29, 30].
The present study included individuals or families with PAI for which the cause was
unknown. In 13 families (19 affected individuals), massively parallel sequencing revealed the
rs6161 (c.940G.A, p.Glu314Lys) variant in CYP11A1 in compound heterozygosity with
another very rare and/or deleterious variant.We showed that the rs6161 variant and two rare
Figure 3. Sequence analysis of in vivo splicing in patient 1 and his parents. (A) RT-PCR
amplification products using primers in exons 4 and 6 of CYP11A1. Lanes 1 and 2, patient 1
and his mother, showing two bands corresponding to transcripts containing exon 5 (upper
band) and skipping exon 5 (lower band); this was confirmed by Sanger sequencing. In
contrast, in lane 3, the father showed only the upper, exon 5 containing, transcript. (B)
Partial chromatograms from Sanger sequencing of the upper bands in the patient, mother,
and father. For the c.990G.A change (Right), the patient and father’s sequence revealed
only the WT c.990G (white arrows), suggesting that the c.990A variant results in exon
skipping and destruction of the truncated mRNA by NMD. For c.940G.A (Left), the patient’s
sequence only has the mutant c.940A allele A inherited from his mother (black arrow),
corroborating the NMD destruction of the c.990A allele inherited from his father; if it were
present, it would give a heterozygous base at this position. In contrast, the mother’s
sequence shows both WT G and a small peak of the mutant A (black arrow), consistent with
skipping of mutant exon 5 in most mutant transcripts but revealing the presence of some
transcripts containing exon 5.
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synonymous variants (Thr330 = and Ser391 =) can cause missplicing, resulting in absent or
dysfunctional proteins and thereby contributing to the pathogenesis in PAI. In our cohort,
compound heterozygosity for the c.940G.A with a second disruptive variant accounted
for .20% of undiagnosed PAI and was one of the most common causes of familial PAI. Our
observations are supported by the recent case report of compound heterozygosity for c.940G.A
with a disruptive splice variant (c.425+1G.A) in a boy with an indolent presentation of PAI
from 3 years of age and a history of hypospadias [14]. The relatively highMAF of rs6161 in the
population (~ in 120 Europeans are carriers) suggests a natural “pool” of this variant is present
in this population and can manifest a phenotype when combined with a very rare disruptive
variant in trans. Four individuals in gnomAD (of 138,595 individuals or 277190 alleles) were
homozygous for rs6161 (c.G.940A). However, it is not knownwhether thiswas associated with
any adrenal phenotype.
Clinically, most affected individuals included in the present study were at the mild end of
the spectrum, with a diagnosis of “familial glucocorticoid deficiency” or “Addison disease.”For
Figure 4. The p.314Lys protein evaluation. (A) Side-chain cleavage activity of CYP11A1
mutant p.314Lys was unaltered in E. coli. Expression of the purified mutant protein in E.
coli showed comparable activity (black bars) as the WT enzyme (gray bars). The activity of
the mutant p.314Lys was determined to be indistinguishable from WT protein, whether the
substrate was 22R-hydroxycholesterol (Left) or cholesterol (Right). (B) The p.314Lys variant
exhibited altered protein expression compared with WT when expressed in HEK-293T cells.
HEK-293T cells were transiently transfected with either WT CYP11A1 or p.314Lys constructs
and cultured for 48 hours. For the indicated times before protein collection, the cells were
treated with 25 mM cycloheximide (CHX). Whole cell lysates were analyzed by immunoblot
and probed with anti-CYP11A1 and anti–glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
antibodies. For the WT, a full-length protein was observed at 60 kDa. In contrast, for the
p.314Lys mutant, the protein was truncated to 30 to 35 kDa, consistent with a cleavage
event around the site of the amino acid change. CHX treatment revealed the mutant
protein also had a shorter half-life.
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most, onset occurred during childhood, rather than in the neonatal period, and hypoglycemic
convulsions or ketotic hypoglycemia were a common feature. Others had a more indolent
course during adolescence or had PAI diagnosed only because of a family history and mild
symptoms, highlighting the importance of diagnosing PAI and investigating “at risk” in-
dividuals. Glucocorticoid insufficiency was common to all affected individuals; however,
approximately one-half required mineralocorticoid replacement, and disordered sex devel-
opment did not occur. Four males experienced delayed puberty; however, the others had
progressed through puberty normally, and two older men had fathered children. However,
monitoring of mineralocorticoid activity and gonadal function will be needed for long-term
management, and more detailed long-term studies are required to understand the natural
history of this condition. Heterozygous parents appear unaffected, as usual for disorders
of steroidogenesis.
The rs6161 allele alters splicing of the pre-mRNA sequence, with the result that many
RNA transcripts do not include exon 5. The transcripts that do include exon 5 will result in a
mutant protein with an amino acid change, glutamic acid to lysine, at residue 314. Although
the mutation reverses the charge on this side chain from negative to positive, the residue is
located on the surface of the protein in the I-helix facing solvent and has no effect on protein
function. Given this ambiguity, we subsequently showed that the purified p.314Lysmutation
has normal spectral and catalytic properties in E. coli but results in an unstable truncated
protein of 30 to 35 kDa when expressed inmammalian cells. In vivo, in affected individuals, it
is likely that the combination of defective splicing and protein dysfunction will result in low
levels of functional, full-length protein derived from this allele. This might be sufficient for
gonadal steroidogenesis but insufficient for glucocorticoid production. Furthermore, our
studies have only been possible in skin fibroblasts or nonsteroidogenic cells; thus, it is
possible that greater residual function occurs in the adrenal gland or gonad.
Tools for the prediction of the functional effects of nonsynonymous variants are well-
established [31]; however, these might not predict the effect such changes will have on
splicing. In particular, variants causing benign amino acid changes might have their effect on
mRNA processing or post-translational modification. Synonymous or “silent” changes are
often ignored and, when tested, the results from commonly used prediction tools might prove
inconclusive. Up to 45% of synonymous SNPs are likely to alter pre-mRNA splicing, and
regulatory information could be dispersed throughout nearly every nucleotide in an exon [32,
33], making it important to consider them in variant analyses, especially when very rare and
discovered in known or likely causative genes.
4. Conclusion
We have concluded that the rs6161 change, in conjunction with another loss-of-function
allele, is responsible for a substantial proportion of unsolved PAI, especially in European
populations. The results of the present study have highlighted the limitations of relying on
common in silico prediction tools and the necessity for individual assessment of a poly-
morphism. This assessment should consider, not only the protein function in a suitable cell
line and assay system, but also the consequences of the change at the nucleic acid level.
Table 3. CYP11A1 Activity in Transfected V79 Cells
Pregnenolone Formed (pg/well)
CYP11A1 6 h 24 h
Wild-type 23,238 6 3919 48,113 6 10369
R460W 105 6 28 388 6 226
L335P 84 6 15 73 6 19
E314K 83 6 3 86 6 30
218 | Journal of the Endocrine Society | doi: 10.1210/js.2018-00130
Appendix
Web Resources
Human Splicing Finder 3.0: http://www.umd.be/HSF3/
Mutation Taster: http://www.mutationtaster.org/
PolyPhen-2: http://genetics.bwh.harvard.edu/pph2/
Sorting Intolerant from Tolerant (SIFT): http://provean.jcvi.org/genome_submit_2.php
dbSNP: www.ncbi.nlm.nih.gov/SNP/
Exome Aggregation Consortium (ExAC), Cambridge, MA: http://exac.broadinstitute.org;
accessed February 2018
The Genome Aggregation Database: http://gnomad.broadinstitute.org/; accessed February
2018
Variant effect predictor: http://www.ensembl.org/Tools/VEP
Online Mendelian Inheritance in Man (OMIM): http://www.omim.org/
The Human Gene Mutation Database: http://www.hgmd.cf.ac.uk/ac/index.php
Ingenuity variant analysis: http://www.ingenuity.com/
Otogenetics: http://www.otogenetics.com/
ESEfinder 3.0: http://krainer01.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home
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